These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

643 related items for PubMed ID: 22879539

  • 1. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses.
    Haroche J, Charlotte F, Arnaud L, von Deimling A, Hélias-Rodzewicz Z, Hervier B, Cohen-Aubart F, Launay D, Lesot A, Mokhtari K, Canioni D, Galmiche L, Rose C, Schmalzing M, Croockewit S, Kambouchner M, Copin MC, Fraitag S, Sahm F, Brousse N, Amoura Z, Donadieu J, Emile JF.
    Blood; 2012 Sep 27; 120(13):2700-3. PubMed ID: 22879539
    [Abstract] [Full Text] [Related]

  • 2. BRAF V600E mutation in Juvenile Xanthogranuloma family neoplasms of the central nervous system (CNS-JXG): a revised diagnostic algorithm to include pediatric Erdheim-Chester disease.
    Picarsic J, Pysher T, Zhou H, Fluchel M, Pettit T, Whitehead M, Surrey LF, Harding B, Goldstein G, Fellig Y, Weintraub M, Mobley BC, Sharples PM, Sulis ML, Diamond EL, Jaffe R, Shekdar K, Santi M.
    Acta Neuropathol Commun; 2019 Nov 04; 7(1):168. PubMed ID: 31685033
    [Abstract] [Full Text] [Related]

  • 3. BRAF V600E mutations are not an oncogenic driver of solitary xanthogranuloma and reticulohistiocytoma: Testing may be useful in screening for Erdheim-Chester disease.
    Hoyt BS, Yan S, Linos KD, Momtahen S, Sriharan A, Tran TN, Tsongalis GJ, O'Meara RR, Green DC, LeBlanc RE.
    Exp Mol Pathol; 2019 Dec 04; 111():104320. PubMed ID: 31639332
    [Abstract] [Full Text] [Related]

  • 4. Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1.
    Gatalica Z, Bilalovic N, Palazzo JP, Bender RP, Swensen J, Millis SZ, Vranic S, Von Hoff D, Arceci RJ.
    Oncotarget; 2015 Aug 14; 6(23):19819-25. PubMed ID: 26110571
    [Abstract] [Full Text] [Related]

  • 5. Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.
    Diamond EL, Subbiah V, Lockhart AC, Blay JY, Puzanov I, Chau I, Raje NS, Wolf J, Erinjeri JP, Torrisi J, Lacouture M, Elez E, Martínez-Valle F, Durham B, Arcila ME, Ulaner G, Abdel-Wahab O, Pitcher B, Makrutzki M, Riehl T, Baselga J, Hyman DM.
    JAMA Oncol; 2018 Mar 01; 4(3):384-388. PubMed ID: 29188284
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of clinicopathologic characteristics and the BRAF V600E mutation in Erdheim-Chester disease among Chinese adults.
    Cao XX, Sun J, Li J, Zhong DR, Niu N, Duan MH, Liang ZY, Zhou DB.
    Ann Hematol; 2016 Apr 01; 95(5):745-50. PubMed ID: 26858028
    [Abstract] [Full Text] [Related]

  • 7. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation.
    Haroche J, Cohen-Aubart F, Emile JF, Arnaud L, Maksud P, Charlotte F, Cluzel P, Drier A, Hervier B, Benameur N, Besnard S, Donadieu J, Amoura Z.
    Blood; 2013 Feb 28; 121(9):1495-500. PubMed ID: 23258922
    [Abstract] [Full Text] [Related]

  • 8. Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation.
    Hervier B, Haroche J, Arnaud L, Charlotte F, Donadieu J, Néel A, Lifermann F, Villabona C, Graffin B, Hermine O, Rigolet A, Roubille C, Hachulla E, Carmoi T, Bézier M, Meignin V, Conrad M, Marie L, Kostrzewa E, Michot JM, Barete S, Taly V, Cury K, Emile JF, Amoura Z, French Histiocytoses Study Group.
    Blood; 2014 Aug 14; 124(7):1119-26. PubMed ID: 24894769
    [Abstract] [Full Text] [Related]

  • 9. Molecular and clinicopathologic characterization of pediatric histiocytoses.
    Hélias-Rodzewicz Z, Donadieu J, Terrones N, Barkaoui MA, Lambilliotte A, Moshous D, Thomas C, Azarnoush S, Pasquet M, Mansuy L, Aladjidi N, Jeziorski E, Marec-Berard P, Gilibert-Yvert M, Spiegel A, Saultier P, Pellier I, Pagnier A, Pertuisel S, Poiree M, Bodet D, Millot F, Isfan F, Stephan JL, Leruste A, Rigaud C, Filhon B, Carausu L, Reguerre Y, Kieffer I, Brichard B, Ben Jannet R, Bakari M, Idbaih A, Bodemer C, Cohen-Aubart F, Haroche J, Tazi A, Boudjemaa S, Fraitag S, Emile JF, Heritier S, French Histiocytosis Study Group.
    Am J Hematol; 2023 Jul 14; 98(7):1058-1069. PubMed ID: 37115038
    [Abstract] [Full Text] [Related]

  • 10. Impact of BRAFV600E mutation on aggressiveness and outcomes in adult clonal histiocytosis.
    Razanamahery J, Godot A, Leguy-Seguin V, Samson M, Audia S, Bonnotte B.
    Front Immunol; 2023 Jul 14; 14():1260193. PubMed ID: 37809108
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Systemic Histiocytosis (Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Destombes-Rosai-Dorfman Disease): from Oncogenic Mutations to Inflammatory Disorders.
    Papo M, Cohen-Aubart F, Trefond L, Bauvois A, Amoura Z, Emile JF, Haroche J.
    Curr Oncol Rep; 2019 May 21; 21(7):62. PubMed ID: 31115724
    [Abstract] [Full Text] [Related]

  • 13. Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults.
    Milne P, Bigley V, Bacon CM, Néel A, McGovern N, Bomken S, Haniffa M, Diamond EL, Durham BH, Visser J, Hunt D, Gunawardena H, Macheta M, McClain KL, Allen C, Abdel-Wahab O, Collin M.
    Blood; 2017 Jul 13; 130(2):167-175. PubMed ID: 28512190
    [Abstract] [Full Text] [Related]

  • 14. Hypoalphalipoproteinemia and BRAFV600E Mutation Are Major Predictors of Aortic Infiltration in the Erdheim-Chester Disease.
    Cohen-Aubart F, Guerin M, Poupel L, Cluzel P, Saint-Charles F, Charlotte F, Arsafi Y, Emile JF, Frisdal E, Le Goff C, Donadieu J, Amoura Z, Lesnik P, Haroche J, Le Goff W.
    Arterioscler Thromb Vasc Biol; 2018 Aug 13; 38(8):1913-1925. PubMed ID: 29930009
    [Abstract] [Full Text] [Related]

  • 15. Langerhans cell histiocytosis and Erdheim-Chester disease, both with cutaneous presentations, and papillary thyroid carcinoma all harboring the BRAF(V600E) mutation.
    Johnson WT, Patel P, Hernandez A, Grandinetti LM, Huen AC, Marks S, Ho J, Monaco SE, Jaffe R, Picarsic J.
    J Cutan Pathol; 2016 Mar 13; 43(3):270-5. PubMed ID: 26454140
    [Abstract] [Full Text] [Related]

  • 16. The clinical spectrum and prognostic factors of Erdheim-Chester disease and mixed Langerhans cell histiocytosis and Erdheim-Chester disease.
    Dai JW, Lin H, Chang L, Li J, Zhou DB, Cao XX.
    Ann Hematol; 2023 Dec 13; 102(12):3335-3343. PubMed ID: 37922006
    [Abstract] [Full Text] [Related]

  • 17. Uncommon histiocytic disorders: Rosai-Dorfman, juvenile xanthogranuloma, and Erdheim-Chester disease.
    Haroche J, Abla O.
    Hematology Am Soc Hematol Educ Program; 2015 Dec 13; 2015():571-8. PubMed ID: 26637774
    [Abstract] [Full Text] [Related]

  • 18. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease.
    Haroche J, Cohen-Aubart F, Emile JF, Maksud P, Drier A, Tolédano D, Barete S, Charlotte F, Cluzel P, Donadieu J, Benameur N, Grenier PA, Besnard S, Ory JP, Lifermann F, Idbaih A, Granel B, Graffin B, Hervier B, Arnaud L, Amoura Z.
    J Clin Oncol; 2015 Feb 10; 33(5):411-8. PubMed ID: 25422482
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Status of Langerhans cell histiocytosis in children and adults].
    Kudo K.
    Rinsho Ketsueki; 2019 Feb 10; 60(9):1308-1316. PubMed ID: 31597857
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.